Rhenman & Partners Asset Management Ab Chimerix Inc Transaction History

Rhenman & Partners Asset Management Ab

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2019 Jul 22, 2019	SELL	$2.05 - $4.32 $141,105 - $297,354	-68,832 Closed	0 $0
Q1 2019 Apr 11, 2019	SELL	$1.79 - $3.12 $281,473 - $490,613	-157,248 Reduced 69.55%	68,832 $145,000
Q4 2018 Feb 05, 2019	SELL	$2.24 - $3.9 $258,092 - $449,358	-115,220 Reduced 33.76%	226,080 $581,000
Q3 2018 Oct 03, 2018	SELL	$3.58 - $4.9 $2,506 - $3,430	-700 Reduced 0.2%	341,300 $1.33 Million
Q4 2017 Jan 19, 2018	SELL	$4.32 - $5.52 $250,560 - $320,160	-58,000 Reduced 14.5%	342,000 $1.58 Million

Q3 2017 Oct 13, 2017	BUY	$4.35 - $5.25 $1.74 Million - $2.1 Million	400,000	400,000 $2.1 Million

29.6M

18.9K

40.9K

Ticker CMRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 87,622,896
Market Cap $73.6M
Description
Chimerix, Inc., a biopharmaceutical company, develops medicines to enhance the lives of patients living with serious diseases. The company's approved product is TEMBEXA (brincidofovir), a lipid conjugate through inhibition of viral DNA synthesis that is developed as a medical countermeasure for smallpox. Its clinical stage development programs i...

Get notified when there are updates to the investment portfolio of Rhenman & Partners Asset Management Ab, based on Form 13F filings with the SEC.

Stay updated on Rhenman & Partners Asset Management Ab with notifications on news.